Bicycle Therapeutics
BCYC
79 hedge funds and large institutions have $538M invested in Bicycle Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 10 closing their positions.
41% more capital invested
Capital invested by funds: $381M → $538M (+$157M)
1.38% more ownership
Funds ownership: 76.55% → 77.93% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more call options, than puts
Call options by funds: $18K | Put options by funds: $18K
2% less funds holding
Funds holding: 81 → 79 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
24% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$20.1M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.46M |
| 3 |
Janus Henderson Group
London,
|
+$7.29M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.14M |
| 5 |
SC
Samlyn Capital
New York
|
+$6.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$7.88M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.64M |
| 3 |
Millennium Management
New York
|
-$4.54M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.51M |
| 5 |
Two Sigma Advisers
New York
|
-$3.63M |
BCYC Hedge Fund Activity: Q3 2022 in Review
79 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q3 2022, worth a combined $538M — up 41% from $381M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BCYC and 8 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 22 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $20.1M. The largest seller was Two Sigma Investments, cutting an estimated $7.88M.
- 79 institutional investors held Bicycle Therapeutics (BCYC) as of Q3 2022, down from 81 in Q2 2022.
- Funds reported $538M of Bicycle Therapeutics stock for Q3 2022, up 41% quarter-over-quarter.
- 8 funds opened new Bicycle Therapeutics positions in Q3 2022 and 10 closed out, a net change of -2 holders.
- The largest Bicycle Therapeutics buyer in Q3 2022 was Baker Bros. Advisors, an estimated $20.1M added.
- The largest Bicycle Therapeutics seller in Q3 2022 was Two Sigma Investments, an estimated $7.88M sold.
Based on aggregated 13F filings for Q3 2022.